Technology Overview

This ADC technology enables precise drug delivery to cancer cells while sparing healthy cells. ITRI offers two patented linker technologies: a glycopeptide linker that improves ADC stability and reduces toxicity, and a site-specific linker that enables uniform conjugation and simplified manufacturing, accelerating ADC development.